MT-2

Melanotan II (MT-2) is a synthetic peptide that mimics the action of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring peptide hormone. It is a non-selective agonist of melanocortin receptors (MC1, MC3, MC4, and MC5). Its primary research interest lies in its ability to induce melanogenesis, leading to skin pigmentation, and its potential effects on sexual arousal and erectile function through activation of MC4 receptors. Beyond its well-known effects on pigmentation, MT-2 has been investigated for its influence on various physiological processes. Activation of MC4 receptors in the central nervous system is implicated in its observed effects on appetite suppression and sexual behavior. Research aims to understand the precise mechanisms by which MT-2 exerts these effects and to differentiate them from other melanocortin receptor agonists.

Research into Melanotan II primarily focuses on its interaction with the melanocortin receptor system. Studies have shown that MT-2 binds to and activates MC1 receptors, leading to increased production of melanin by melanocytes, which results in skin darkening. This mechanism is distinct from UV radiation-induced tanning, offering a potential avenue for photoprotection research. Furthermore, MT-2's agonistic activity at the MC4 receptor has garnered significant attention for its potential role in sexual function. Preclinical studies have indicated that activation of MC4 receptors in the brain can modulate sexual arousal and erectile function. This has led to investigations into its therapeutic potential for conditions like erectile dysfunction, with some research suggesting a dose-dependent pro-erectile effect. Other research explores its impact on appetite and metabolism via MC3 and MC4 receptor activation, though these effects are often secondary to its more prominent pigmentation and sexual function effects. All research is for scientific study only and not for human use. It is important to note that MT-2 is a research chemical and has not been approved for human use. Its effects and safety profile in humans are not fully established outside of controlled research settings.

Typical research protocols involving Melanotan II suggest dosages ranging from 0.25 mg to 1 mg administered subcutaneously. Frequency and duration of administration vary based on the specific research objective, such as studying melanogenesis or sexual function. All dosing information is for research reference only.